Scholarlink

Background <p>Chronic hepatitis B (CHB) is a major global health issue, with interferon (IFN)-based therapy playing a key role in achieving sustained virological response and immune-mediated viral clearance. This study analyzed global research trends, collaborative networks, and emerging priorities in interferon therapy for CHB.</p> Methods <p>A comprehensive literature search was conducted using the Web of Science Core Collection database. Bibliometric tools, including VOSviewer, CiteSpace, and R-bibliometrix, were employed.</p> Results <p>A total of 2,035 studies were analyzed, showing a steady increase in publication activity. China led in research output (891 publications), followed by the USA (172) and Japan (128). Leading institutions included Capital Medical University (211 publications), Fudan University (208), and National Taiwan University (200). Influential journals included <i>Hepatology</i> (h-index = 43), <i>Journal of Hepatology</i> (h-index = 42), and <i>Journal of Viral Hepatitis</i> (h-index = 26). The most prominent authors were Harry L. A. Janssen (TP = 66), Bettina E. Hansen (TP = 39), and Patrick Marcellin (TP = 44). The top three keywords were “therapy” (489 occurrences, total link strength: 2045), “lamivudine” (409 occurrences, total link strength: 2013), and “combination” (243 occurrences, total link strength: 1249). Keywords burst analysis highlighted emerging trends, including “functional cure” (2021–2024), “hbsag loss” (2021–2024), “entecavir” (2019–2024), and “guidelines” (2017–2024).</p> Conclusions <p>This bibliometric analysis identifies critical research areas in interferon therapy for CHB, emphasizing advancements in immune mechanisms, therapeutic optimization, and pharmacological innovation. Future research should focus on functional cures, refining treatment guidelines, and integrating innovative strategies to improve clinical outcomes.</p> Clinical trial number <p>not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月1日

查看全文
  • Lei Duan,
  • Yang Liu,
  • Dingyu Wu,
  • Ting Wen,
  • Song Huang,
  • Xiuyun Zhu,
  • Guangyan Sun,
  • Guohong Yang,
  • Yinbao Hu,
  • Shoucui Pu,
  • Qiangwei Zeng,
  • Qingyu Yang

摘要

Background

Chronic hepatitis B (CHB) is a major global health issue, with interferon (IFN)-based therapy playing a key role in achieving sustained virological response and immune-mediated viral clearance. This study analyzed global research trends, collaborative networks, and emerging priorities in interferon therapy for CHB.

Methods

A comprehensive literature search was conducted using the Web of Science Core Collection database. Bibliometric tools, including VOSviewer, CiteSpace, and R-bibliometrix, were employed.

Results

A total of 2,035 studies were analyzed, showing a steady increase in publication activity. China led in research output (891 publications), followed by the USA (172) and Japan (128). Leading institutions included Capital Medical University (211 publications), Fudan University (208), and National Taiwan University (200). Influential journals included Hepatology (h-index = 43), Journal of Hepatology (h-index = 42), and Journal of Viral Hepatitis (h-index = 26). The most prominent authors were Harry L. A. Janssen (TP = 66), Bettina E. Hansen (TP = 39), and Patrick Marcellin (TP = 44). The top three keywords were “therapy” (489 occurrences, total link strength: 2045), “lamivudine” (409 occurrences, total link strength: 2013), and “combination” (243 occurrences, total link strength: 1249). Keywords burst analysis highlighted emerging trends, including “functional cure” (2021–2024), “hbsag loss” (2021–2024), “entecavir” (2019–2024), and “guidelines” (2017–2024).

Conclusions

This bibliometric analysis identifies critical research areas in interferon therapy for CHB, emphasizing advancements in immune mechanisms, therapeutic optimization, and pharmacological innovation. Future research should focus on functional cures, refining treatment guidelines, and integrating innovative strategies to improve clinical outcomes.

Clinical trial number

not applicable.